This is the authors' abstract. We don't add key points for this paper.
BackgroundManagement of pregnancy in chronic myeloid leukemia (CML) is challenging, particularly in resource-limited settings where access to molecular monitoring and pregnancy-compatible therapies is constrained.Tyrosine kinase inhibitors (TKIs), while highly effective, are teratogenic and often require interruption, risking disease destabilization.Real-world data from low-and middle-income countries remain limited.
No takes yet. Share an insight, caveat, or question.
Quero-Taggaoa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: